DR-132 ctDNA analysis to monitor response to neoadjuvant chemoradiation in esohageal cancer patients
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-132 ctDNA analysis to monitor response to neoadjuvant chemoradiation in esohageal cancer patients
“After treatment with a combination of chemotherapy and radiotherapy for esophageal cancer, the current standard treatment is to continue with …
DR-131 The link between the immunologic and genomic characteristics of patients with metastatic melanoma and the possible effect on response to (immuno)therapy.
“Since almost 10 years, the outcome of patients with metastatic melanoma has improved significantly and long term durable responses have …
DR-129 Comparing metastatic and primary breast tumours through the lens of integrated subtypes
The Personalised Breast Cancer Program (PBCP) is an initiative based at the Cancer Research UK Cambridge Institute and the Addenbrooke’s …
DR-127 “Genetic causes of resistance to new androgen receptor signaling inhibitors in metastasized castration-resistant prostate cancer patients. DR-127 is an extension of DR-013”
“Androgen receptor inhibitors (ARi) are frequently used to treat metastatic prostate carcinomas. In this project, we focus on identifying genetic …
DR-125 Characterizing genome instability profiles in human cancers
We aim to understand the molecular mechanisms leading to the high degree of mutability observed in certain types of tumors …
DR-123 Pan-cancer RNA landscape analysis to explain functional changes, identify novel biomarkers and therapeutic targets
We recently finalized an extensive genomic analysis of breast and prostate cancer, which provided important novel insights into the biology …
DR-121 Refining the candidate identification of germline and somatic variation with a functional role in metastatic cancers
Priestley et al. (2019), the study introducing the Hartwig Medical Foundation data collection, used several state-of-the-art analysis tools for calling …
DR-118 The role of chromosomal catastrophe in breast cancer pathogenesis
HER2-positive breast cancer is an aggressive subtype driven by amplification of the Her2/Erbb2 gene. This oncogene is thought to be …
DR-115 The association between the homozygous germline deletion of chromosome 8 (ADAM3A region) and survival of patients with the tumours of digestive system treated with different regimens.
Oesophageal adenocarcinoma (EAC) is an aggressive cancer with a poor overall prognosis. Our data from shallow sequencing of 95 patients …
DR-099 PEGASUS – Pancreatic and EsophagoGastric cAncer, improving Survival and qUality of life through personalized medicine
Pancreatic cancer and esophagogastric cancer are among the most deadly forms of cancer: despite intensive treatment with chemotherapy and / …
DR-095 Towards the clinical implementation of whole-genome sequencing (WGS) to guide precision oncology
If we are able to better predict who will respond to treatment, this could have major implications for clinical practice. …
DR-094 RNA (immune) markers in non-small cell lung cancer patients treated with immune checkpoint inhibitors (RIMINI)
Immunotherapy can achieve great results for NSCLC patients, yet this costly therapy is only efficient in a small number of …
Een complete DNA-test biedt bij patiënten met PTO de extra mogelijkheid om erachter te komen waar de kanker is begonnen. Hierdoor wordt vaak de primaire tumor toch gevonden. Daarnaast geeft de test vaak aanknopingspunten voor een gerichte behandeling.